Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2002

View Archived Issues

Merck & Co. outlines new cycle of breakthrough medicines at San Francisco conference

Amylin concentrating its efforts on two late-stage, first-in-class products

Antisense oligodeoxynucleotide targeting Bid inhibits bile acid-induced liver injury

Novel class of potent and selective 5-HT1A ligands designed at Servier

Biogen highlights two superstar candidates from robust pipeline

Access Oncology obtains rights to noncardiotoxic anthracyclines

Acorda chooses spasticity as fampridine lead indication

Antisense anticancer agent achieves clinical milestone

Cyclic glycopeptide antibiotics discovered to have attractive properties at Wyeth-Ayerst

Highly immunogenic malaria vaccine candidate heads for the clinic

Antex extends manufacturing agreement for vaccines

Neurotech licenses Amgen's CNTF for ophthalmic indications

InFUSE Bone Graft recommended for approval for spinal fusion by FDA panel

ComGenex and Solvo file patent application for drug candidates from collaboration

CollaGenex expands into dermatology

Positive results from phase II trial of SomatoKine in type 2 diabetes

Eos transfers lead antibody target to Pharmacopeia; companies in the process of merging

PhotoCure submits MAA for Metvix PDT in Switzerland

Disappointing preliminary results from first phase III trial of INS-3 Ophthalmic in dry eye

Keryx licenses novel technology for small-molecule drug design

New series of PARP inhibitors and their potential therapeutic uses described by Guilford

Cholecystokin and gastrin receptor ligands in development at James Black Foundation

Meiji Seika patents two related series of progesterone receptor antagonists

Antagonists of NPY Y5 receptors reportedly useful for eating disorders, diabetes

Recent patents cover Roche's new lactam muscarinic receptor antagonists

Diazabicyclic nicotinic cholinergic receptor ligands designed at Targacept

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...